Catabasis Pharmaceuticals (NASDAQ:CATB) Releases Earnings Results, Misses Estimates By $0.06 EPS

Catabasis Pharmaceuticals (NASDAQ:CATB) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.06), Bloomberg Earnings reports.

Shares of Catabasis Pharmaceuticals stock traded down $0.05 during midday trading on Friday, hitting $6.56. The company had a trading volume of 19,468 shares, compared to its average volume of 36,163. The company’s 50 day moving average price is $7.30. The company has a market cap of $76.01 million, a PE ratio of -1.28 and a beta of 1.73. The company has a current ratio of 12.25, a quick ratio of 12.25 and a debt-to-equity ratio of 0.01. Catabasis Pharmaceuticals has a 1-year low of $3.60 and a 1-year high of $9.76.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Catabasis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 16th. Wedbush restated an “outperform” rating and issued a $18.00 price objective on shares of Catabasis Pharmaceuticals in a research note on Monday, July 29th. Finally, ValuEngine upgraded shares of Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday.



Several institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in Catabasis Pharmaceuticals during the first quarter worth $142,000. Bank of Montreal Can acquired a new stake in Catabasis Pharmaceuticals during the first quarter worth $75,000. Oppenheimer & Co. Inc. boosted its stake in Catabasis Pharmaceuticals by 97.3% during the first quarter. Oppenheimer & Co. Inc. now owns 91,884 shares of the biotechnology company’s stock worth $727,000 after buying an additional 45,303 shares in the last quarter. Federated Investors Inc. PA boosted its stake in Catabasis Pharmaceuticals by 109.8% during the first quarter. Federated Investors Inc. PA now owns 2,189,400 shares of the biotechnology company’s stock worth $17,340,000 after buying an additional 1,146,000 shares in the last quarter. Finally, Wells Fargo & Company MN acquired a new stake in Catabasis Pharmaceuticals during the second quarter worth $82,000. Institutional investors and hedge funds own 36.38% of the company’s stock.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD).

Recommended Story: What is the definition of a trade war?

Earnings History for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.